Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Codexis Dropped as Much as 14.6% Today

By Maxx Chatsko - Mar 9, 2018 at 3:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small cap biotech company provided disappointing guidance for 2018.

What happened

Shares of engineered enzyme leader Codexis (CDXS 4.01%) dropped over 14% today after the company reported full-year 2017 earnings and provided guidance for the year ahead. The business performed well last year as the company's novel enzyme engineering platform gained traction with new customers. That wasn't exactly a surprise, however, for investors who followed the results from the first nine months of 2017.

The disappointment came from full-year 2018 guidance. While total revenue is expected to rise 20% to 26% compared to 2017, the increase will be driven by collaboration revenue. Product revenue growth is expected to be relatively flat, which is a bit surprising considering product revenue soared 74% last year compared to 2016.

Despite the disappointment on guidance and significant drop in share prices in early trading, as of 2:23 p.m. EST Codexis stock had clawed its way back to a gain of 1.9%.

A chart on a chalkboard sliding down.

Image source: Getty Images.

So what

Codexis turned in its best year of operations ever in 2017.

Metric

2017

2016

Percent Change

Total revenue

$50.0 million

$48.8 million

2.5%

Collaboration revenue

$20.7 million

$31.3 million

(34%)

Product revenue

$26.7 million

$15.3 million

75%

Product gross margin

46%

36%

28%

Net income

($23 million)

($8.6 million)

N/A

Source: Codexis.

That said, not all of the progress shows up in the company's financial results. For instance, Codexis had to replace $22 million in non-recurring revenue from 2016 in 2017. Product sales -- the least volatile source of revenue -- picked up the slack last year. In 2018, new collaboration revenue will take its turn to carry the business.

Therein lies the surprise. Codexis issued full-year 2018 guidance that calls for total revenue of $60 million to $63 million, which would represent growth of 20% to 26% from 2017. However, product revenue will fall in the range of $25 million to $28 million. Considering that the company was expected to increase sales to food ingredient manufacturing applications and is launching a new line of enzymes for next-generation sequencing (NGS) applications, it's easy to see why Mr. Market is disappointed.

Now what

The sudden flattening in product revenue growth should be a speed bump rather than a brick wall for the business over the long term. The food ingredients partner is ramping up a new production process, which should enable the highest volume opportunity for product sales in the near future. Throw in an exciting opportunity in the NGS market and plans to begin clinical trials for Codexis' first biotherapeutic enzyme, and 2018 may not be as boring as the company's guidance seemed to indicate.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Codexis, Inc. Stock Quote
Codexis, Inc.
CDXS
$10.88 (4.01%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.